Biotech entity
pharma is the sole category represented across all 1 tracked stories. BioMarin Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Summit Therapeutics appears in 1 tracked Biotech story from February 20, 2026. The tracked stories average 4 original sources each.
Last mentioned: Feb 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. BioMarin Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Summit Therapeutics appears in 1 tracked Biotech story from February 20, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Summit Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Summit Therapeutics and its mid-cap biotech peers are set to report Q4 2025 results, with investor focus centered on Summit's ivonescimab commercialization path and BioMarin's Voxzogo expansion. These reports will serve as a critical barometer for the sector's ability to transition from R&D-heavy pipelines to sustainable commercial growth.
Summit Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
